GlassScriptPhysician profile
Richard A Henderson
NPI 1427002336
$14,048.31
in general payments reported to CMS, 2019-2025
48 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $1,785 · 2021: $2,176 · 2022: $2,534 · 2023: $2,556 · 2024: $1,670 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,914 · Education: $62.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,914.08 |
| Education | $62.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,444.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,425.36 | 2019-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $1,103.34 | 2019-2025 | |
| Novo Nordisk INC | $868.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $781.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $718.41 | 2020-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $704.46 | 2021-2025 | |
| Glaxosmithkline, LLC. | $672.81 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $542.21 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $509.04 | 2019-2025 | Eliquis |
| Abbvie INC. | $472.26 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $423.38 | 2019-2025 | Gattex |
| Radius Health, INC. | $421.58 | 2019-2025 | Tymlos |
| Astellas Pharma US INC | $379.12 | 2019-2025 | Veozah |
| Pfizer INC. | $344.21 | 2019-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.